Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination

Vaccine

Volumn 31, Issue 9, 2013, Pages 1293-1297

  Paulke Korinek, Maria ^a   Kundi, Michael ^b   Laaber, Brigitte ^a   Brodtraeger, Natascha ^a   Seidl Friedrich, Claudia ^a   Wiedermann, Ursula ^a   Kollaritsch, Herwig ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna   (Austria)

Author keywords

Antibody persistence; Booster properties; Follow up; Immunization schedule; Long term; Tick borne encephalitis

Indexed keywords

TICK BORNE ENCEPHALITIS VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNITY; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUSES, TICK-BORNE; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; TIME FACTORS; VACCINATION; VIRAL VACCINES; YOUNG ADULT;

EID: 84873435767     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.075     Document Type: Article

References (35)

1. Rendi-Wagner P. Advances in vaccination against tick-borne encephalitis. Expert Rev Vaccines 2008, 7(5):589-596.
2. Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008, 22(3):561-575.
3. Süss J. Tick-borne encephalitis in Europe and beyond-the epidemiological situation as of 2007. Euro Surveill 2008, 13.(26).
4. Kollaritsch H., Paulke-Korinek M., Holzmann H., Hombach J., Bjorvatn B., Barrett A. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines 2012, 11(9):1103-1119.
5. Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm. Euro Surveill 2009;14(36):pii=19325. Available from: [accessed 15.10.12]. http://www.eurosurveillance.org/ViewArticle.aspx%3FArticleId=19325.
6. World Health Organization Vaccines against tick-borne encephalitis: WHO position paper. WER 2011, 24(86):241-256.
7. Kunz C. TBE vaccination and the Austrian experience. Vaccine 2003, 21(S 1):S50-S55.
8. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25(43):7559-7567.
9. Jelenik Z., Keller M., Briggs B., Günther G., Haglund M., Hudeckova H., et al. Congress report: tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne Encephalitis (ISW-TBE). Wien Med Wochenschr 2010, 160(9-10):247-251.
10. Rendi-Wagner P., Kundi M., Zent O., Dvorak G., Jaehnig P., Holzmann H., et al. Persistence of protective immunity following vaccination against tick-borne encephalitis-longer than expected?. Vaccine 2004, 22(21-22):2743-2749.
11. Schosser R., Kaiser R., Mansmann U., Heininger U. Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4.5 years since the last TBE vaccination. International Jena Symposium on Tick Borne Diseases 2009.
12. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Laaber B., Wiedermann U., Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine 2009, 27(50):7027-7030.
13. Plentz A., Jilg W., Schwarz T.F., Kuhr H.B., Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults. Vaccine 2009, 27(6):853-856.
14. Rendi-Wagner P., Kundi M., Zent O., Banzhoff A., Jaehnig P., Stemberger R., et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 2004, 23(4):427-434.
15. Rendi-Wagner P., Paulke-Korinek M., Kundi M., Wiedermann U., Laaber B., Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 2007, 25(27):5097-5101.
16. Stiasny K., Kiermayr S., Holzmann H., Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 2006, 80(19):9557-9568.
17. Holzmann H., Kundi M., Stiasny K., Clement J., McKenna P., Kunz C., et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol 1996, 48(1):102-107.
18. Kreil T., Burger I., Bachmann M., Fraiss S., Eibl M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 1997, 110(3):358-361.
19. Klockmann U., Bock H.L., Kwasny H., Praus M., Cihlová V., Tomková E., et al. Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization. Vaccine 1991, 9(1):42-46.
20. Kaml M., Weiskirchner I., Keller M., Luft T., Hoster E., Hasford J., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24(47-48):6808-6811.
21. Hainz U., Jenewein B., Asch E., Pfeiffer K.P., Berger P., Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005, 23(25):3232-3235.
22. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Firth C., Petermann R., et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 2011, 29(43):7307-7319.
23. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Koska M., Bobrovsky R., et al. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5ml in adults aged 18-67 years. Hum Vaccines 2009, 5(8):551-556.
24. Stiasny K., Aberle J.H., Keller M., Grubeck-Loebenstein B., Heinz F.X. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS ONE 2012, 7(3):e34145.
25. Weinberger B., Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect 2012, 18(S5):100-108.
26. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine 2003, 21(Suppl. 1):S36-S40.
27. Rendi-Wagner P., Korinek M., Winkler B., Kundi M., Kollaritsch H., Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007, 25(5):927-931.
28. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rumke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24(15):2781-2789.
29. Schuller E., Klade C.S., Heinz F.X., Kollaritsch H., Rendi-Wagner P., Jilma B., et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008, 26(48):6151-6156.
30. Orlinger K.K., Hofmeister Y., Fritz R., Holzer G.W., Falkner F.G., Unger B., et al. A tick-borne encephalitis vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis 2011, 203(11):1556-1564.
31. Mansfield K.L., Horton D.L., Johnson N., Li L., Barrett A.D., Smith D.J., et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol 2011, 92(Pt 12):2821-2829.
32. Blanco-Quiros A., Garcia-Marcos L., Garrote J.A., Martinez-Torres A.E., Leon A. Antibody levels to Bordetella pertussis in 10-yr-old children with atopy and atopic asthma. Pediatr Allergy Immunol 2005, 16(8):637-640.
33. Prescott S.L., Macaubas C., Smallacombe T., Holt B.J., Sly P.D., Holt P.G. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999, 353(9148):196-200.
34. Abbas A., Lichtman A., Pillai S. Cellular and molecular immunology 2007, Saunders Elsevier, Philadelphia, USA.
35. Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C., Corti D., Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 2006, 211:303-309.